<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155946</url>
  </required_header>
  <id_info>
    <org_study_id>N1534-R</org_study_id>
    <nct_id>NCT02155946</nct_id>
  </id_info>
  <brief_title>Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment</brief_title>
  <official_title>Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aging US population threatens to overwhelm our healthcare infrastructure, especially
      since the rate of Alzheimer's disease (AD) alone is expected to triple in the coming decades.
      Memory cause functional impairment, reduced quality of life, increased caregiver burnout, and
      eventual institutionalization. The diagnosis of mild cognitive impairment (MCI) identifies
      those with memory deficits but who remain relatively independent in everyday life. MCI
      provides a window for interventions that target memory functioning. The proposed study
      focuses specifically on a groundbreaking combination of mnemonic rehabilitation and
      non-invasive brain stimulation. The main idea is that brain stimulation can enhance
      functioning in the specific brain regions/networks, thereby increasing the patients' ability
      to benefit from different types of memory rehabilitation. This will be a randomized,
      double-blind study (active vs. fake brain stimulation), that provides multiple treatment
      session. Outcome will be examined using both laboratory-based and real-world memory testing
      as well as brain imaging. This first-of-its-kind study has the potential to meaningfully
      translate more &quot;basic&quot; science findings into neuroanatomically targeted and functionally
      meaningful treatments for our aging population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional MRI</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in task related and resting state BOLD activation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Face-name memory test performance</measure>
    <time_frame>change from baseline</time_frame>
    <description>Performance measured using percent correct</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Object Location Association memory test performance</measure>
    <time_frame>change from baseline</time_frame>
    <description>Performance measured using deviation from target position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI</measure>
    <time_frame>change from baseline to 3 months</time_frame>
    <description>Changes in task related and resting state BOLD activation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Face-name memory test performance</measure>
    <time_frame>change from baseline to 3 months</time_frame>
    <description>Performance measured using percent correct</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Object Location Association memory test performance</measure>
    <time_frame>change from baseline to 3 months</time_frame>
    <description>Performance measured using deviation from target position</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective memory test performance</measure>
    <time_frame>3 months</time_frame>
    <description>Performance on prose (medical instructions) and spatial (navigation) memory tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective memory test performance on the MMQ</measure>
    <time_frame>3 months</time_frame>
    <description>Changes on the Multifactorial Memory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective memory test performance</measure>
    <time_frame>change from baseline to 3 months</time_frame>
    <description>Performance on prose (medical instructions) and spatial (navigation) memory tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective memory test performance on the MMQ</measure>
    <time_frame>change from baseline to 3 months</time_frame>
    <description>Changes on the Multifactorial Memory Questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Planned (tertiary) analyses of patient-specific characteristics that affect treatment outcome</measure>
    <time_frame>post treatment (within ~ 96 hours) &amp; 3 months</time_frame>
    <description>Planned analyses to examine patient specific characteristics that affect treatment efficacy and would be vital for clinical translation at the individual patient level. These include: Neuropsychological test scores, brain volumes/cortical thickness, and other possible MRI factors.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receives active brain stimulation plus memory rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group receives sham brain stimulation plus memory rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receives active brain stimulation plus reminiscence training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receives sham brain stimulation plus reminiscence training</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit</intervention_name>
    <description>Active brain stimulation</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit</intervention_name>
    <description>Sham (placebo)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit</intervention_name>
    <description>Active brain stimulation</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit</intervention_name>
    <description>Sham (placebo)</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General inclusion criteria (all patients):

          -  All medications stable for approximately 2-3 months;

          -  No history of severe mental illness;

          -  No current untreated alcohol or substance abuse/dependence;

          -  English as native and preferred language;

          -  MRI-compatible if taking part in fMRI studies

          -  Able to give informed consent.

        MCI Inclusion Criteria:

        - Diagnosis of amnestic MCI based on criteria set forth by Petersen (2004). Additionally,
        other potential causes of cognitive deficit ruled out by the referring physician

        Exclusion Criteria:

          -  History of neurological disease or injury

          -  History of severe mental illness

          -  Current untreated alcohol or substance abuse

          -  Other conditions may exclude; please discuss with contact
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin M. Hampstead, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System, Ann Arbor, MI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin M Hampstead, PhD</last_name>
    <phone>(404) 321-6111</phone>
    <phone_ext>5006</phone_ext>
    <email>bhampste@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliver C Calhoun</last_name>
    <email>occ@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System, Ann Arbor, MI</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin M Hampstead, PhD</last_name>
      <phone>404-321-6111</phone>
      <phone_ext>5006</phone_ext>
      <email>bhampste@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin M. Hampstead, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Alzheimer's Disease/Dementia</keyword>
  <keyword>Cognitive Disorders</keyword>
  <keyword>Imaging</keyword>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <keyword>Neurology</keyword>
  <keyword>Physical Medicine &amp; Rehabilitation</keyword>
  <keyword>transcranial direct current stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

